Cullinan Therapeutics Reports $49.7 Million Net Loss in Q1 2026

Cullinan Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $49.7 million, compared to a net loss of $48.5 million for the same period in 2025. The company's total operating expenses decreased slightly to $53.7 million from $55.0 million year-over-year, primarily due to a reduction in general and administrative expenses, which fell from $13.5 million to $11.6 million. Research and development expenses remained relatively stable, increasing marginally from $41.5 million to $42.1 million, reflecting ongoing investments in clinical trials and product development.

In terms of cash flow, Cullinan reported a net cash outflow from operating activities of $46.0 million for the first quarter of 2026, compared to $43.2 million in the prior year. The company’s cash and cash equivalents, along with short-term investments, totaled $351.9 million as of March 31, 2026, down from $386.8 million at the end of 2025. This decline was attributed to the ongoing operational losses and cash used in operations, although the company also generated $32.4 million from investing activities during the quarter, primarily from the maturities of marketable securities.

Strategically, Cullinan has made significant advancements in its clinical pipeline. The company is actively developing several product candidates, including CLN-978, a T cell engager for autoimmune diseases, and zipalertinib, an EGFR inhibitor for non-small cell lung cancer, which has recently had its new drug application accepted by the FDA. Additionally, Cullinan entered into a sales agreement with TD Securities to establish an at-the-market equity offering program, allowing it to raise up to $200 million in common stock, which could provide essential funding for ongoing and future projects.

Operationally, Cullinan continues to focus on its research and development efforts, with a particular emphasis on clinical trials for its lead candidates. The company is also exploring potential collaborations and licensing agreements to enhance its product pipeline. As of March 31, 2026, Cullinan had an accumulated deficit of $637.8 million, reflecting its history of significant operating losses since inception. The company anticipates continued losses as it invests in the development of its therapies, with no revenue generated from product sales to date.

Looking ahead, Cullinan's management remains optimistic about the potential of its product candidates and the overall market for its therapies. However, they acknowledge the inherent risks and uncertainties associated with drug development, including regulatory approvals and market conditions. The company plans to leverage its current cash reserves and potential future financing to support its ongoing research and development activities, while also monitoring global economic conditions that could impact its operations.